Therapeutic developments in pancreatic cancer: current and future perspectives
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic developments in pancreatic cancer: current and future perspectives
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume 15, Issue 6, Pages 333-348
Publisher
Springer Nature
Online
2018-05-01
DOI
10.1038/s41575-018-0005-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Alok A. Khorana et al. JOURNAL OF CLINICAL ONCOLOGY
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
- (2017) Edward P. Balaban et al. Journal of Oncology Practice
- Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer
- (2017) Atsushi Sofuni et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Locally Advanced Pancreatic Cancer
- (2016) Thilo Hackert et al. ANNALS OF SURGERY
- Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer
- (2016) Steffi J. Rombouts et al. ANNALS OF SURGICAL ONCOLOGY
- Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
- (2016) Gary Middleton et al. BRITISH JOURNAL OF CANCER
- Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer
- (2016) Christian Bauer et al. CANCER LETTERS
- Immunotherapy and tumor microenvironment
- (2016) Haidong Tang et al. CANCER LETTERS
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- A Breakthrough: Macrophage-Directed Cancer Immunotherapy
- (2016) C. D. Mills et al. CANCER RESEARCH
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
- (2016) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Ablation Strategies for Locally Advanced Pancreatic Cancer
- (2016) Michael Linecker et al. DIGESTIVE SURGERY
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer
- (2016) Qingda Meng et al. JOURNAL OF IMMUNOTHERAPY
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation
- (2016) Stefan W. Ryter et al. Translational Research
- Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
- (2016) Eva Versteijne et al. Trials
- Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review
- (2016) Salvatore Paiella et al. Gastroenterology Research and Practice
- Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists
- (2016) Soraya Zorro Manrique et al. Oncotarget
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
- (2015) B. H. O'Neil et al. ANNALS OF ONCOLOGY
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
- (2015) G. Deplanque et al. ANNALS OF ONCOLOGY
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience
- (2015) Ulrich Nitsche et al. ANNALS OF SURGICAL ONCOLOGY
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
- (2015) Zheng Wu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210
- (2015) Muhammad Zaeem Noman et al. CANCER RESEARCH
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer
- (2015) Sylvia F. Boj et al. CELL
- Systemic Immune Activity Predicts Overall Survival in Treatment-Nai ve Patients with Metastatic Pancreatic Cancer
- (2015) M. R. Farren et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
- (2015) L. A. Chantrill et al. CLINICAL CANCER RESEARCH
- Role of indoleamine 2,3-dioxygenase in health and disease
- (2015) Amanda W.S. Yeung et al. CLINICAL SCIENCE
- Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
- (2015) Adnan M. Nagrial et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
- (2015) Doraid Alrifai et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Cancer immunotherapy: Strategies for personalization and combinatorial approaches
- (2015) Vishwanath Sathyanarayanan et al. Molecular Oncology
- Patient-centric trials for therapeutic development in precision oncology
- (2015) Andrew V. Biankin et al. NATURE
- Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
- (2015) Yaron Carmi et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer
- (2015) Fausto Petrelli et al. PANCREAS
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Special Conference on Tumor Immunology and Immunotherapy: A New Chapter
- (2015) K. T. Byrne et al. Cancer Immunology Research
- Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
- (2015) Laura Rosa Brunet et al. OncoImmunology
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)
- (2014) Michael Tachezy et al. BMC CANCER
- Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer
- (2014) S. J. E. Rombouts et al. BRITISH JOURNAL OF SURGERY
- Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
- (2014) Philip A. Philip et al. CANCER
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
- (2014) Berna C. Özdemir et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
- (2014) Heloisa P. Soares et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
- (2014) T. Dragovich et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
- (2014) D. T. Weed et al. CLINICAL CANCER RESEARCH
- Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
- (2014) Cindy Serdjebi et al. Expert Opinion on Drug Metabolism & Toxicology
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study
- (2014) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway
- (2014) Alban Bessede et al. NATURE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study
- (2014) F. Ge et al. ONCOLOGIST
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
- (2014) Maximilian Bockhorn et al. SURGERY
- Intervention on toll-like receptors in pancreatic cancer
- (2014) Juan Vaz WORLD JOURNAL OF GASTROENTEROLOGY
- nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer
- (2014) A. Neesse et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
- (2014) D. T. Fearon Cancer Immunology Research
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
- (2013) Muhammad Wasif Saif et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunotherapy with TCR-Redirected T Cells: Comparison of TCR-Transduced and TCR-Engineered Hematopoietic Stem Cell-Derived T Cells
- (2013) L. Starck et al. JOURNAL OF IMMUNOLOGY
- Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function
- (2013) K. S. Voo et al. JOURNAL OF IMMUNOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Improvement of surgical results for pancreatic cancer
- (2013) Werner Hartwig et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
- (2013) Robert Wesolowski et al. Journal for ImmunoTherapy of Cancer
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Current concepts and novel targets in advanced pancreatic cancer
- (2012) Patrick Michl et al. GUT
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
- (2011) Stefan Heinrich et al. BMC CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- StellaTUM: current consensus and discussion on pancreatic stellate cell research
- (2011) Mert Erkan et al. GUT
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Outcome of High-Intensity Focused Ultrasound in Advanced Pancreatic Cancer
- (2011) Hye Young Sung et al. PANCREAS
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
- (2010) K. Potthoff et al. ANNALS OF ONCOLOGY
- Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
- (2010) Hedy Lee Kindler et al. INVESTIGATIONAL NEW DRUGS
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses
- (2009) A. P. Lepique et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search